Loestrin Buyers' Attys Seek $43M From Antitrust Deal

The legal team that helped direct buyers of birth control Loestrin snag a $120 million deal with drugmakers Warner Chilcott and Watson Pharmaceuticals over antitrust and fraud allegations is seeking just...

Already a subscriber? Click here to view full article